Abstract Details

Title Comparison of DRD2, DRD3 and NMDA Receptor Genotype Polymorphisms in Parkinson's Patients and Controls

Topic Movement Disorders

Presentation(s) IN2 - (-)

Poster/Presentation
Number 007

Objective

Background Impulse control disorders (ICDs) in Parkinson disease are associated with DRD3, DRD2 and NMDA receptor genotype polymorphisms. However it is unknown whether these genotype receptor polymorphisms are associated with susceptibility to PD.

Design/Methods Genotype polymorphism analysis for rs1800497 (DRD2), rs6280 (DRD3), and rs7301328 (NMDA GRIN 2B) was performed on stored blood of 664 PD patients and 718 normal controls. Demographic and clinical data was recorded. There was no departure from Hardy-Weinberg equilibrium in study controls (P>0.05). Single-SNP associations with PD were evaluated using logistic regression models adjusted for age and gender. Additive, dominant and recessive models were utilized.

Results There was evidence of an association between rs1800497 and PD under an additive model (OR:1.31, P=0.0065), and a dominant model (OR: 1.36, P=0.0096) with a non-significant trend towards association under a recessive model (OR:1.54, P=0.12). There was an association between rs7301328 and PD under a dominant model (OR: 1.26, P=0.048) but not under an additive model (OR: 1.11, P=0.20) or recessive model (OR: 0.97, P=0.86). There was no evidence of an association with PD for rs6280 under any statistical model (all P?0.73).

Conclusions DRD2 (rs1800497) and NMDA GRIN 2B (rs7301328) receptor polymorphisms may contribute to the risk of PD, but not DRD3 (rs6280). Extending our study to compare patients with and without ICDs in the PD cohort is warranted to further define the relationship.

Authors/Disclosures
Anhar Hassan, MBBCH, FRACP, FRCPI, FAAN (Beaumont Hospital) PRESENTER	The institution of Dr. Hassan has received research support from Intrabio . Dr. Hassan has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with Korean Movement Disorders Society.
Michael S. Okun, MD, FAAN (University of Florida)	Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
J. E. Ahlskog, MD, PhD (Mayo Clinic)	Dr. Ahlskog has received publishing royalties from a publication relating to health care.
Owen A. Ross, PhD (Mayo Clinic Jacksonville)	Dr. Ross has nothing to disclose.
Liana Apostolova, MD, FAAN (Indiana University School of Medicine)	Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NIH. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Apostolova has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Association. An immediate family member of Dr. Apostolova has stock in Cassava Neurosciences. The institution of Dr. Apostolova has received research support from Roche Diagnostics. The institution of Dr. Apostolova has received research support from NIA. The institution of Dr. Apostolova has received research support from Alzheimer Association. The institution of Dr. Apostolova has received research support from AVID radiopharmaceuticals. The institution of Dr. Apostolova has received research support from Life Molecular Imaging.

��ɫ��

��ɫ��